Next Article in Journal
Application of Dominance-Based Rough Set Approach for Optimization of Pellets Tableting Process
Next Article in Special Issue
Oral Insulin Delivery Using Poly (Styrene Co-Maleic Acid) Micelles in a Diabetic Mouse Model
Previous Article in Journal
Exploiting the Natural Properties of Extracellular Vesicles in Targeted Delivery towards Specific Cells and Tissues
Previous Article in Special Issue
Development and Optimization of Naringenin-Loaded Chitosan-Coated Nanoemulsion for Topical Therapy in Wound Healing
Open AccessReview

Pulmonary Delivery of Biological Drugs

1
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China
2
School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(11), 1025; https://doi.org/10.3390/pharmaceutics12111025
Received: 15 September 2020 / Revised: 13 October 2020 / Accepted: 20 October 2020 / Published: 26 October 2020
(This article belongs to the Special Issue Non-invasive Drug Delivery Systems)
In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery. The main challenges in the formulation and inhalation devices are discussed, together with the possible strategies that can be applied to address these challenges. Current clinical developments in inhaled biological drugs for both local and systemic applications are also discussed to provide an insight for further research. View Full-Text
Keywords: aerosol; inhalation; lung; monoclonal antibodies; therapeutic proteins aerosol; inhalation; lung; monoclonal antibodies; therapeutic proteins
Show Figures

Graphical abstract

MDPI and ACS Style

Liang, W.; Pan, H.W.; Vllasaliu, D.; Lam, J.K.W. Pulmonary Delivery of Biological Drugs. Pharmaceutics 2020, 12, 1025. https://doi.org/10.3390/pharmaceutics12111025

AMA Style

Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary Delivery of Biological Drugs. Pharmaceutics. 2020; 12(11):1025. https://doi.org/10.3390/pharmaceutics12111025

Chicago/Turabian Style

Liang, Wanling; Pan, Harry W.; Vllasaliu, Driton; Lam, Jenny K.W. 2020. "Pulmonary Delivery of Biological Drugs" Pharmaceutics 12, no. 11: 1025. https://doi.org/10.3390/pharmaceutics12111025

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop